BR9814606A - Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus - Google Patents

Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus

Info

Publication number
BR9814606A
BR9814606A BR9814606-8A BR9814606A BR9814606A BR 9814606 A BR9814606 A BR 9814606A BR 9814606 A BR9814606 A BR 9814606A BR 9814606 A BR9814606 A BR 9814606A
Authority
BR
Brazil
Prior art keywords
methods
treating
vaccine formulation
individual infected
hpv virus
Prior art date
Application number
BR9814606-8A
Other languages
English (en)
Inventor
Lutz Gissmann
Martin Mueller
Original Assignee
Univ Loyola Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loyola Chicago filed Critical Univ Loyola Chicago
Publication of BR9814606A publication Critical patent/BR9814606A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Abstract

"FORMULAçãO DE VACINA E MéTODOS DE TRATAMENTO DE UM INDIVìDUO INFECTADO COM UM VIRUS HPV E DE PREVENçãO DE INFECçãO POR PAPILOMA VIRUS". Formulação de vacina compreendendo capsómeros virais são descritas juntamente com métodos para sua produção. Métodos terapêuticos e profiláticos de uso para as formulações de vacina também são descritos.
BR9814606-8A 1997-10-06 1998-10-06 Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus BR9814606A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/944,368 US6228368B1 (en) 1997-10-06 1997-10-06 Papilloma virus capsomere formulations and method of use
PCT/US1998/020965 WO1999018220A1 (en) 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use

Publications (1)

Publication Number Publication Date
BR9814606A true BR9814606A (pt) 2002-01-02

Family

ID=25481268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814606-8A BR9814606A (pt) 1997-10-06 1998-10-06 Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus

Country Status (21)

Country Link
US (4) US6228368B1 (pt)
EP (2) EP1690941B1 (pt)
JP (3) JP4520034B2 (pt)
KR (1) KR20010030969A (pt)
AT (2) ATE449852T1 (pt)
AU (1) AU9684698A (pt)
BR (1) BR9814606A (pt)
CA (1) CA2305382A1 (pt)
CY (1) CY1105963T1 (pt)
CZ (1) CZ302351B6 (pt)
DE (2) DE69841342D1 (pt)
DK (1) DK1021547T3 (pt)
ES (2) ES2280104T3 (pt)
HU (1) HU225893B1 (pt)
IL (3) IL135528A0 (pt)
NO (2) NO328128B1 (pt)
NZ (1) NZ503830A (pt)
PL (1) PL195332B1 (pt)
PT (1) PT1021547E (pt)
TR (1) TR200001842T2 (pt)
WO (1) WO1999018220A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT809700E (pt) * 1994-10-07 2006-09-29 Univ Loyola Chicago Particulas semelhantes ao papilomavirus e proteinas de fusao, assim como metodos para a sua producao
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) * 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
FI107932B (fi) * 1999-02-16 2001-10-31 Mikael Paronen Polymeerikalvo ja menetelmä sen valmistamiseksi
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
ES2325053T3 (es) * 1999-12-09 2009-08-25 Medimmune, Llc Metodo in vitro para desensamblaje/reensamblaje de particulas similares a virus de papilomavirus (vlp).
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
DE10059630A1 (de) * 2000-12-01 2002-06-06 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
US7247433B2 (en) 2001-08-13 2007-07-24 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
WO2003018623A2 (en) * 2001-08-31 2003-03-06 University Of Cape Town Papillomavirus proteins and pharmaceutical compositions
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
EP1506222B2 (en) † 2002-05-17 2012-05-23 University of Cape Town Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide, virus-like particles prepared therefrom and a method for preparing the particles
DK1523329T3 (da) 2002-07-05 2013-10-14 Folia Biotech Inc Viruspartikeladjuvant
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
SE0202896D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method for estimating the risk of carcinoma development
SE0202897D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method and kit for quantitative and qualitative determination of human papillomavirus
WO2004062584A2 (en) * 2003-01-10 2004-07-29 Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7172773B2 (en) * 2004-04-26 2007-02-06 Renew Life Inc. Food supplement formulation
CN101010099B (zh) * 2004-09-10 2011-11-09 旭硝子株式会社 口服疫苗
DE602005022759D1 (de) 2004-12-08 2010-09-16 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US8748127B2 (en) * 2007-05-29 2014-06-10 Xiamen University Truncated L1 protein of human papillomavirus type 6
US8507811B2 (en) * 2009-02-02 2013-08-13 Apple Inc. Touch sensor panels with reduced static capacitance
EP2377879A1 (en) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum N-terminal HPV E7 fusion proteins
US10413603B2 (en) 2014-06-19 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for improved human papilloma virus constructs
WO2016026919A1 (en) * 2014-08-20 2016-02-25 Ruprecht-Karls-Universität Heidelberg Vaccines and manufacturing methods for treatment and prevention of disease
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
US11382700B2 (en) 2020-05-08 2022-07-12 Globus Medical Inc. Extended reality headset tool tracking and control
US11510750B2 (en) 2020-05-08 2022-11-29 Globus Medical, Inc. Leveraging two-dimensional digital imaging and communication in medicine imagery in three-dimensional extended reality applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0595935T3 (da) 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
ATE380871T1 (de) 1992-06-25 2007-12-15 Univ Georgetown Papillomavirus vakzine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
PT809700E (pt) * 1994-10-07 2006-09-29 Univ Loyola Chicago Particulas semelhantes ao papilomavirus e proteinas de fusao, assim como metodos para a sua producao
DE4447664C2 (de) 1994-10-07 1999-04-15 Lutz Prof Dr Gissmann Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
JP3413020B2 (ja) * 1996-07-17 2003-06-03 株式会社東芝 半導体装置の製造方法
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
CA2295316C (en) * 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
GB2333782B (en) 1997-08-26 2002-09-04 Nsk Ltd Method of manufacturing rolling bearings
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
JP2010095530A (ja) 2010-04-30
US20090028894A1 (en) 2009-01-29
EP1021547B1 (en) 2006-12-27
NZ503830A (en) 2002-09-27
IL190554A0 (en) 2008-11-03
JP2013147507A (ja) 2013-08-01
CY1105963T1 (el) 2011-04-06
IL135528A (en) 2008-06-05
ATE449852T1 (de) 2009-12-15
US20050031636A1 (en) 2005-02-10
DE69841342D1 (de) 2010-01-07
TR200001842T2 (tr) 2000-12-21
DK1021547T3 (da) 2007-04-23
US7754430B2 (en) 2010-07-13
PT1021547E (pt) 2007-02-28
US6228368B1 (en) 2001-05-08
EP1021547A1 (en) 2000-07-26
PL195332B1 (pl) 2007-09-28
CA2305382A1 (en) 1999-04-15
JP5296665B2 (ja) 2013-09-25
ATE349536T1 (de) 2007-01-15
WO1999018220A1 (en) 1999-04-15
NO328128B1 (no) 2009-12-14
EP1690941A1 (en) 2006-08-16
JP4520034B2 (ja) 2010-08-04
JP2001519161A (ja) 2001-10-23
EP1690941B1 (en) 2009-11-25
US7371391B2 (en) 2008-05-13
CZ302351B6 (cs) 2011-03-30
KR20010030969A (ko) 2001-04-16
NO20001768L (no) 2000-06-02
PL339735A1 (en) 2001-01-02
ES2337492T3 (es) 2010-04-26
IL135528A0 (en) 2001-05-20
DE69836753D1 (de) 2007-02-08
AU9684698A (en) 1999-04-27
US20060198853A1 (en) 2006-09-07
HUP0004360A2 (en) 2001-03-28
NO20091761L (no) 2000-06-02
ES2280104T3 (es) 2007-09-01
CZ20001244A3 (en) 2001-05-16
DE69836753T2 (de) 2007-10-25
HUP0004360A3 (en) 2003-03-28
HU225893B1 (en) 2007-12-28
NO20001768D0 (no) 2000-04-06

Similar Documents

Publication Publication Date Title
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
FI940054A0 (fi) Peptider av humant papillomavirus foer anvaendning i kompositioner som inducerar human T-cellsvar
WO1999033868A3 (en) Human papillomavirus vaccine
EP1820853A3 (en) Recombinant influenza viruses for vaccines and gene therapy
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
DE69535018D1 (de) Papillomavirus vakzine
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
HUP9900389A3 (en) Mixture of recombinant viruses as polyenv vaccines for hiv, preparation and use thereof
FI965224A (fi) Polynukleotidirokote papilloomavirukselle
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
HUP0303942A2 (hu) Új vakcinakészítmények
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
EP0366238A3 (en) Influenza vaccinal polypeptides
DE69527294T2 (de) 4-[2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl]-2-cyclopenten-1-methanol-succinat als antivirales mittel
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
NZ512850A (en) Treatment of papillomavirus infections
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time